{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:24Z","timestamp":1787008584867,"version":"build-2736575974"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Methotrexate-induced liver fibrosis is not a well-defined pathology, and many of the reported cases can instead be classified as nonalcoholic fatty liver disease by current diagnostic criteria, which is particularly common in the psoriasis cohort. Liver fibrosis usually takes many years to progress; therefore, screening for liver fibrosis should be done no more regularly than annually at the very most in dermatology practice. An algorithm is presented about how to investigate abnormal liver blood tests and screening tools for liver fibrosis are compared.<\/jats:p>","DOI":"10.1093\/ced\/llac083","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T20:57:42Z","timestamp":1673125062000},"page":"303-309","source":"Crossref","is-referenced-by-count":4,"title":["Liver fibrosis for the dermatologist: a review"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4037-6585","authenticated-orcid":false,"given":"Mina M","family":"Raahimi","sequence":"first","affiliation":[{"name":"Departments of Dermatology , Portsmouth Hospitals University NHS Trust , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Livesey","sequence":"additional","affiliation":[{"name":"Departments of Dermatology , Portsmouth Hospitals University NHS Trust , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Departments of Dermatology , Portsmouth Hospitals University NHS Trust , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa R","family":"Shipman","sequence":"additional","affiliation":[{"name":"Departments of Dermatology , Portsmouth Hospitals University NHS Trust , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Aspinall","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology and Hepatology, Portsmouth Hospitals University NHS Trust , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"2023100315293831800_llac083-B1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.4254\/wjh.v9.i26.1092","article-title":"Risk of liver disease in methotrexate treated patients","volume":"9","author":"Conway","year":"2017","journal-title":"World J Hepatol"},{"key":"2023100315293831800_llac083-B2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/archderm.1970.04000120031005","article-title":"Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis","volume":"102","author":"Weinstein","year":"1970","journal-title":"Arch Dermatol"},{"key":"2023100315293831800_llac083-B3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archderm.1971.04000150020003","article-title":"Hepatotoxicity of methotrexate in the treatment of psoriasis","volume":"103","author":"Roenigk","year":"1971","journal-title":"Arch Dermatol"},{"issue":"Suppl. 2","key":"2023100315293831800_llac083-B4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","article-title":"Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity","volume":"25","author":"Montaudi\u00e9","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100315293831800_llac083-B5","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2023100315293831800_llac083-B6","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archderm.143.12.1515","article-title":"Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens","volume":"143","author":"Berends","year":"2007","journal-title":"Arch Dermatol"},{"key":"2023100315293831800_llac083-B7","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/gut.2003.019984","article-title":"Long term prognosis of fatty liver: risk of chronic liver disease and death","volume":"53","author":"Dam-Larsen","year":"2004","journal-title":"Gut"},{"key":"2023100315293831800_llac083-B8","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"2023100315293831800_llac083-B9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"2023100315293831800_llac083-B10","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1172\/JCI93465","article-title":"Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis","volume":"127","author":"Caussy","year":"2017","journal-title":"J Clin Invest"},{"key":"2023100315293831800_llac083-B11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"2023100315293831800_llac083-B12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2023100315293831800_llac083-B13","article-title":"Prevalence of metabolic syndrome in patients with psoriasis","volume":"312463","author":"Zindanc\u0131","year":"2012","journal-title":"Sci World J"},{"key":"2023100315293831800_llac083-B14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","article-title":"Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55\u2005years old or older: results from a population-based study","volume":"70","author":"van der Voort","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023100315293831800_llac083-B15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023100315293831800_llac083-B16","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.fertnstert.2012.10.040","article-title":"Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis","volume":"99","author":"Moro","year":"2013","journal-title":"Fertil Steril"},{"key":"2023100315293831800_llac083-B17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/1346-8138.15178","article-title":"Thyroid dysfunction in patients with psoriasis: higher prevalence of thyroid dysfunction in patients with generalized pustular psoriasis","volume":"47","author":"Namiki","year":"2020","journal-title":"J Dermatol"},{"key":"2023100315293831800_llac083-B18","doi-asserted-by":"crossref","first-page":"e055538","DOI":"10.1136\/bmjopen-2021-055538","article-title":"Prevalence of autoimmune thyroid disease in patients with psoriasis: a meta-analysis","volume":"12","author":"Zhang","year":"2022","journal-title":"BMJ Open"},{"key":"2023100315293831800_llac083-B19","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2023100315293831800_llac083-B20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-62834-x","article-title":"Bidirectional association between psoriasis and obstructive sleep apnea: a systematic review and meta-analysis","volume":"10","author":"Ger","year":"2020","journal-title":"Sci Rep"},{"issue":"3 Pt 1","key":"2023100315293831800_llac083-B21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"2023100315293831800_llac083-B22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease \u2013 a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"2023100315293831800_llac083-B23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/ajg.2017.5","article-title":"Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey Data","volume":"112","author":"Kabbany","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2023100315293831800_llac083-B24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/jdv.12847","article-title":"Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis","volume":"29","author":"Candia","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100315293831800_llac083-B25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease \u2013 meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"Suppl. 3","key":"2023100315293831800_llac083-B26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jdv.12163","article-title":"Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review","volume":"27","author":"Horreau","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100315293831800_llac083-B27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2468-1253(22)00061-9","article-title":"Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group","volume":"7","author":"McPherson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023100315293831800_llac083-B28","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(14)61838-9","article-title":"Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis","volume":"384","author":"Williams","year":"2014","journal-title":"Lancet"},{"key":"2023100315293831800_llac083-B29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/flgastro-2021-101833","article-title":"Identification of liver disease: why and how","volume":"13","author":"Macpherson","year":"2022","journal-title":"Frontline Gastroenterol"},{"key":"2023100315293831800_llac083-B30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2018","journal-title":"Gut"},{"key":"2023100315293831800_llac083-B31","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1365-2133.2011.10345.x","article-title":"Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress","volume":"164","author":"McAleer","year":"2011","journal-title":"Br J Dermatol"},{"key":"2023100315293831800_llac083-B32","first-page":"595","article-title":"Alcohol and the skin","volume":"27","author":"Higgins","year":"1992","journal-title":"Alcohol Alcohol"},{"key":"2023100315293831800_llac083-B33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/oxfordjournals.alcalc.a008254","article-title":"Isoforms of transferrin in psoriasis patients abusing alcohol","volume":"32","author":"Hoefkens","year":"1997","journal-title":"Alcohol Alcohol"},{"key":"2023100315293831800_llac083-B34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023100315293831800_llac083-B35","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"2023100315293831800_llac083-B36","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/hep.1840220616","article-title":"The natural history of nonalcoholic fatty liver: a follow-up study","volume":"22","author":"Teli","year":"1995","journal-title":"Hepatology"},{"key":"2023100315293831800_llac083-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19090","article-title":"Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation","volume":"19","author":"Crossan","year":"2015","journal-title":"Health Technol Assess"},{"key":"2023100315293831800_llac083-B38","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023100315293831800_llac083-B39","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hep.20935","article-title":"A novel panel of blood markers to assess the degree of liver fibrosis","volume":"42","author":"Cal\u00e8s","year":"2005","journal-title":"Hepatology"},{"key":"2023100315293831800_llac083-B40","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"2023100315293831800_llac083-B41","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"2023100315293831800_llac083-B42","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"2023100315293831800_llac083-B43","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/bjd.12905","article-title":"Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis","volume":"170","author":"Maybury","year":"2014","journal-title":"Br J Dermatol"},{"key":"2023100315293831800_llac083-B44","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"key":"2023100315293831800_llac083-B45","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"2023100315293831800_llac083-B46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2023100315293831800_llac083-B47","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cgh.2010.09.015","article-title":"A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis","volume":"9","author":"Alkhouri","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl. 4","key":"2023100315293831800_llac083-B48","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1542\/peds.2007-2329C","article-title":"Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report","volume":"120","author":"Barlow","year":"2007","journal-title":"Pediatrics"},{"key":"2023100315293831800_llac083-B49","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00393-021-00976-7","article-title":"[Patient safety in the treatment of rheumatic diseases: laboratory monitoring in methotrexate treatment]","volume":"80","author":"Sierocinski","year":"2021","journal-title":"Z Rheumatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llac083\/48505693\/llac083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/4\/303\/51836379\/llac083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/4\/303\/51836379\/llac083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:19:01Z","timestamp":1696339141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/4\/303\/6931756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,19]]},"published-print":{"date-parts":[[2023,3,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llac083","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2022,12,19]]}}}